Australia's largest stock trading and investment forum Australia's #1 stock forum

AVH

3.24%

$2.99 avita medical inc.

Impressive bit of added news, more reduced stays and reduced...

First 26 Last

Share
Profile

Follow
compint

644 Posts.

344

29/05/24

22:48

Post #: 74072787
Share

Originally posted by saltland: ↑

It's reassuring to see the standard of care and cost savings improving when combining RECELL and SUPRATHEL:

Comparative results of autologous skin cell suspension combined with a contact layer dressing versus autologous skin cell suspension and a poly-lactic acid dressing in larger total body surface burns
Brandon M. Larson, Djoni Elkady, Steffi Sharma, Beverly Beaucock, Richard B. Lou, Anjay Khandelwal

Highlights
• Current standard post-burn surgery dressings are nonadherent, contact layer.
• Poly-lactic acid dressings can be combined with an autologous skin cell suspension.
• Poly-lactic acid dressings can decrease infections and hospital costs.

Abstract

Introduction
Contact layer dressing (CLD) is standard after autologous skin cell suspension (ASCS); however, the authors wondered whether a poly-lactic acid dressing (PLAD) results in superior outcomes and cost savings.

Material and methods
Retrospective cohort study including greater than 10% total body surface area (TBSA) burns treated with ASCS and either PLAD or CLD. Primary outcomes were infection and length of stay (LOS).

Results
71 patients (76% male, 24% pediatric, mean age 37 years) were included. Twenty-eight patients (39%) received CLD and 43 (61%) received PLAD. Wound infections were decreased in PLAD (7 vs 32%, p = 0.009). When controlling for area grafted (cm2) and TBSA, logistic regression revealed odds of post-operative infection was 8.1 times higher in CLD (p = 0.015). PLAD required antibiotics for fewer days (mean 0.47 vs 4.39, p = 0.0074) and shorter LOS (mean 17 vs 29 days, p < 0.001). Mean adjusted charges per %TBSA was $18,459 in PLAD vs. $25,397 in CLD (p = 0.0621).

Conclusion
In the first analysis of its kind, this study showed polylactic acid dressing combined with autologous skin cell suspension led to a decrease in postoperative infections, length of hospital stay, and total patient charges.

Conflict of interest statement
Declaration of Competing Interest Dr. Anjay Khandelwal is a consultant for AVITA Medical, Inc.

This evidence should assist with PolyMedic Innovations roll out of RECELL in Germany, Austria, and Switzerland.
Hopefully, we'll see similar studies and articles with RECELL and PermeaDerm in the future.

Expand

Impressive bit of added news, more reduced stays and reduced costs. I am assuming this comes on top of the already stated reduced costs the spray on skin produces when used for burns and wounds. Dare say the medical insurance industry will be very keen give a priority to this fact. The patient insurance costs will remain the same but insurance company will reap the benefit.

AVH Price at posting: $2.74 Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

TRP

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

MM1

Geochemical work at Newington picks up gold and copper anomalies for Midas

PEC

Perpetual sniffs TREOs beyond 4000ppm at Raptor play in Brazil

BGL

Bellevue aims for 45% production increase by FY 2028, announces $150M placement

Capital raisings wrap: Brainchip, Ovanti, Lake and VHM